David Louis Cutchin, Ph.D. 

Background:

Dr. Dave Cutchin's primary interests are in climate of the upper ocean, instrumentation, and scientific administration. 

Significant Contributions and Achievements:

Dr. Cutchin's work history is as follows: From 1962-1963, he worked at General Dynamics Astronautics as an optical physicist. From 1965-1966, at Stanford Research Institute as an operations analyst. During 1966, as a consultant at Litton Industries. From 1971-1973 at the U. of Wisconsin, Center for Great Lakes Studies for his post-doc. From 1973-1975 as an assistant prof. of engineering at the U. of Wisconsin. From 1975-1977 at the NSF-IDOE as the assoc. program manager. From 1977-1991 at  UCSD Scripps Institution of Oceanography, as academic administrator in charge of North Pacific Experiment and Volunteer Observing Ship Program.  He formally retired in 1993 but RTAD (return to active duty part time) to continue with VOS program till 2014. From 1991-1993, Dr. Cutchin worked at the SIO/NSF Center for Clouds, Chemistry & Climate as asst. director.

Education:

Dr. Cutchin earned a BS in Physics from Marquette University in 1962, an MS in Physics from University of New Mexico in 1965, and a Ph.D. in Physical Oceanography from Oregon State University in 1971. 

  

Daryl Smith

Background:

Daryl Smith is the managing partner and co-founder of Kayak Investment Partners. Mr. Smith has built, configured, programmed, and networked computers from an early age. For the past decade, Mr. Smith has pioneered the use of real-time data analytics to track a broad range of internet equities. 

Significant Contributions and Achievements:

Prior to co-founding Kayak Investment Partners, from 2006 to 2012, Mr. Smith headed internet investments at Cavalry Asset Management. From 2004 to 2006, Mr. Smith held similar responsibilities at Andor Capital Management. From 2002 to 2004, Mr. Smith was an analyst at JP Morgan (acquired by Chase Hambrecht & Quist in 2000), covering the internet sector and within nine months was ranked a Top-Ten Analyst by Institutional investor. From 1998 to 2002, Mr. Smith was an analyst at Hambrecht & Quist (acquired by Chase Manhattan Bank in 1999), covering the enterprise software, hardware, distribution, and data storage sectors. 

Education:

In 1998, Mr. Smith earned a BA in History, magna cum laude, from the University of California, Berkeley with a minor in Business Administration from the Haas School of Business. At the University of California, Berkeley, Mr. Smith was a Phi Beta Kappa and Golden Key Honor Society scholar, and received the 1997 Doug Sciutto Memorial Scholarship. 

 

Steve Bordner

Background:

Steve Bordner is a Vice President at CBRE. He started his real estate career with Coldwell Banker Commercial Real Estate in 1980, specializing in transactions on the Eastside. In 1983, he ventured into real estate development with Evergreen Management Company. Steve returned to CBRE in October of 1998 to focus on the leasing and sale of industrial/high-technology and office properties. He is currently a member of Washington State Commercial Association of Realtors. Also, he is a licensed managing broker in the State of Washington.

As a member of a family impacted by ALS, Mr. Bordner is an advocate for the patients and families affected by neurological illness.

Significant Contributions and Achievements:

Prior to re-joining CBRE, Steve was involved in the development, construction, leasing, management and sale of more than 1 million square feet of commercial real estate. Also during that time he was involved in the platting of residential lots, plus the development and construction of single-family and duplex homes. After joining CBRE, Steve earned the CBRE Top 10 designation for Puget Sound region in 2008.

Education:

Steve has a Bachelor of Arts degree in Economics from the University of Washington. He earned his Master of Business Administration, also from the University of Washington.

 

Richard A. Smith, M.D.

Background:

During his neurology residency at Stanford University, Dr. Smith began his first studies of Lou Gehrig's Disease which has remained his principal career interest. His initial studies focused on the symptomatic treatment of ALS but at Scripp's Research Institute, he began to research the cause of ALS and subsequently directed his major effort to developing a therapy for ALS and kindred disorders.

Significant Contributions and Achievements:

His earliest publications in the New England Journal, British Medical Journal, etc. were among the first publications to demonstrate the utility of symptomatic management in the care of ALS patients. Among the first investigator to recognize the potential of interferon as a treatment modality, Dr. Smith's work contributed to the adoption of interferon as one of the first treatments for multiple sclerosis. And, along with colleagues Barry Festoff and Schlomo Melmed, Dr. Smith conducted the first trial of a growth factor (IGF-1) as a treatment for a neurological disease. More recent achievements include the development of DMQ which was approved by FDA in 2011 for the treatment of emotional lability and the development of antisense therapeutics, along with colleagues at UCSD and Isis Pharmaceutical Corp, as potential  treatment for familial neurological disorders such as Huntington's Disease and familial ALS. On June 2014, the ALS Association awarded Dr. Smith an Essey prize for his efforts to develop a treatment for familial ALS.

Education:

Dr. Smith attended Brandeis University and subsequently, received his medical degree from the University of Miami. Following graduation from medical school, he interned at Jackson Memorial Hospital after which he obtained his neurology training at Stanford University.

Randall Kaye, M.D.

Background:

Randall Kaye, MD serves as Chief Science Officer at SSI Strategy, a boutique consulting firm focused on Medical Affairs, Pharmacovigilance and Clinical Development.  In Dr. Kaye’s role at SSI Strategy, he focuses on providing a medical and science perspective to transformative initiatives in Medical Affairs, Clinical Research and Pharmacovigilance.

Significant Contributions and Achievements:

Most recently, Dr. Kaye was Chief Medical Officer at Axsome Therapeutics, a biopharmaceutical company developing novel therapies for the treatment of pain and other neurological diseases. Prior to joining Axsome, Dr. Kaye was Chief Medical Officer at Avanir Pharmaceuticals (acquired by Otsuka), a CNS specialty company. While at Avanir, Dr. Kaye designed, developed and built the clinical, regulatory and medical affairs departments, resulting in the approval and launch of a first in class neurologic therapeutic.

Education:

Dr. Kaye earned his Doctor of Medicine, Masters in Public Health and Bachelor of Science degrees at The George Washington University in Washington, D.C. Dr. Kaye trained in Pediatrics at the University of Massachusetts Medical School and was a Research Fellow at Harvard Medical School.

Non-Board Members

Kathy Myers, Ph.D.

Secretary and Treasurer

Background:

In addition to serving as secretary/treasurer of CNS, Dr. Myers has been employed at the Center since 2013, currently as senior research scientist.

Signficant contributions and achievements:

Dr. Myers’ interests are focused on drug discovery, therapeutics, immunology, and neuroscience. She has worked in the San Diego biotechnology community for the more than 20 years, leading drug discovery research teams in a wide variety of therapeutic areas, and in projects using many therapeutic modalities, including antisense oligonucleotides, siRNA, antibodies, biologics, nanoparticles, and small molecule drugs. She has supervised teams developing drugs targeting inflammatory and autoimmune diseases, fibrosis, transplantation biology, diabetes, osteoarthritis, and osteoporosis, and her efforts have led to three Investigational New Drug Applications (INDs) and nine patents/patent applications. Prior to her career in science, Dr. Myers was a radio and television news reporter.

Education:

Dr. Myers has a bachelor’s degree in history from Duke University and a Ph.D. in immunology from Rutgers University.

 

Jennifer Huang

Administrative and Research Assistant